Ilya Pharma shares latest developments of ILP100-Oral at virtual conference 7th of December showcasing innovations in gut therapeutics

Professor Mia Phillipson will present Nature Conferences Innovative Tissue Therapies from Bench to Bedside 16-18 November

Abstract: "The ILP-technology platform is scalable and enables efficient delivery of immunoregulatory proteins locally on-site – lead program in clinical phase 2 developments"

Ilya Pharma will be participating at Jefferies London Healthcare Conference 16-19 November

Ilya Pharma will be participating at the Swedish American Life Science Summit 2021 October 20-22 and is nominated to the Rising Star Award

Ilya Pharma selected to present at BioFuture 4-8 October in NYC at Cure in the session of "Breakthrough Therapies: Brought to you by Game Changing Technologies!"

Ilya Pharma will present at Microbiome Movement 3-5 August

Open position - Senior Clinical Trials Manager for phase II/III study

Most welcome to come work with us on our next big thing, a phase 2b study starting next year. Position filled.

Ilya Pharma Receives Approval from Swedish Regulators to Initiate Phase II Clinical Study of ILP100 Gene Therapy to Treat Difficult Wounds Patients with Diabetes

Pfizer veteran Sylvia McBrinn joins Board while Oskar Lund becomes CFO as Ilya Pharma strengthens senior management - top news shared by FirstWord Pharma

Ilya Pharma will present recent clinical data and planned studies for ILP100 Topical and Oral at Pharmabiotics 28-29 April 2021